Farr, Olivia M.
Sofopoulos, Michail
Tsoukas, Michael A.
Dincer, Fadime
Thakkar, Bindiya
Sahin-Efe, Ayse
Filippaios, Andreas
Bowers, Jennifer
Srnka, Alexandra
Gavrieli, Anna
Ko, Byung-Joon
Liakou, Chrysoula
Kanyuch, Nickole
Tseleni-Balafouta, Sofia
Mantzoros, Christos S.
Funding for this research was provided by:
Novo Nordisk
NIH Clinical Center (UL1 RR025758)
Article History
Received: 5 November 2015
Accepted: 4 January 2016
First Online: 1 February 2016
Funding
: The project was supported by Harvard Clinical and Translational Science Center Grant UL1 RR025758 from the National Center for Research Resources. Novo Nordisk supported the study through an Investigator-Initiated Study grant and supplied liraglutide/placebo. They approved the design of the study, but had no role in study design, conduct of the study, collection, management, analysis and interpretation of the data or the preparation, review or approval of the manuscript. OMF is supported by a training grant through the NICHD 5T32HD052961.
: OMF wrote the manuscript, analysed the data and researched data. MS and MAT wrote and edited the manuscript and researched data. B-JK and AG analysed the data and reviewed the manuscript. AS-E, FD, AF, JB, AS, NK, CL, ST-B and BT researched data and reviewed the manuscript. CSM composed the protocol, researched data and reviewed and edited the manuscript. OMF is the guarantor of this work. All authors approved the final version of the manuscript.
: CSM has served on the scientific advisory board and is a shareholder of Novo Nordisk. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.
Free to read: This content has been made available to all.